An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

International Journal of Gynecological Pathology

Volumn 35, Issue 5, 2016, Pages 430-441

  Köbel, Martin ^a   Rahimi, Kurosh ^c,d   Rambau, Peter F ^a   Naugler, Christopher ^a,j   Le Page, Cécile ^c,g   Meunier, Liliane ^c,g   De Ladurantaye, Manon ^c,g   Lee, Sandra ^a   Leung, Samuel ^h   Goode, Ellen L ^k   Ramus, Susan J ^l   Carlson, Joseph W ^m   Li, Xiaodong ^b   Ewanowich, Carol A ^b   Kelemen, Linda E ^n,o   Vanderhyden, Barbara ⁱ   Provencher, Diane ^c,e,f   Huntsman, David ^h   Lee, Cheng Han ^b   Gilks, C Blake ^h   Mes Masson, Anne Marie ^c,f,g   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Departments of Pathology   (Canada)

^e Obstetric Gynecology   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g Institut du Cancer de Montreal   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

Histotype; Immunohistochemistry; Next generation sequencing; Ovarian cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; VIMENTIN; WT1 PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CARCINOMA; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HIGH GRADE SEROUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW GRADE SEROUS CARCINOMA; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; AGED; ALGORITHM; CANADA; CLASSIFICATION; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOLOGY; STATISTICAL MODEL; TISSUE MICROARRAY; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; CANADA; CARCINOMA; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84961218591     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000274     Document Type: Article

References (29)

1. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008 5 e232
2. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010 29 203-11.
3. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6
4. Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011;12:1071-80
5. Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011;121:407-15
6. Diaz-Padilla I, Malpica AL, Minig L, et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012;126:279-85
7. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transCanadian study. Am J Surg Pathol 2010;34:984-93
8. Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2013 64 1004-13.
9. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-74
10. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63
11. Soslow RA. DNA repair mutations and outcomes in ovarian cancer-letter. Clin Cancer Res 2015;21:658
12. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
13. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220:392-400
14. Altman AD, Nelson GS, Ghatage P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian highgrade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol 2013;26:1255-63
15. Kalloger SE, Köbel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011;24:512-21
16. Köbel M, Kalloger SE, Lee S, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev 2013;22:1677-86.
17. Kommoss S, Gilks CB, Kommoss F, et al. Accelerating typespecific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology 2013;63:704-12
18. Hoang LN, Zachara S, Soma A, et al. Diagnosis of ovarian carcinoma histotype based on limited sampling: a prospective study comparing cytology, frozen section, and core biopsies to full pathologic examination. Int J Gynecol Pathol 2015;34: 517-27
19. Le Page C, Köbel M, de Ladurantaye M, et al. Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv Biobank 2013;11:83-93
20. Kelemen LE, Warren GB, Koziak JM, et al. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. 2016;140:124-30
21. Mackenzie R, Talhouk A, Eshragh S, et al. Morphologic and molecular characteristics of mixed epithelial ovarian cancers. Am J Surg Pathol 2015;39:1548-57
22. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
23. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73
24. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2013;27:128-34
25. Kandalaft PL, Gown AM, Isacson C. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary. Am J Clin Pathol 2014;142:830-6
26. Lee S, Piskorz A, Le Page C, et al. Calibration and optimization of p53, WT1, and Napsin A immunohistochemistry ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) experience. Int J Gynecol Pathol. Nov 23 2015 [Epub ahead of print]
27. Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013;14:853-62
28. Stewart CJR, Brennan BA, Chan T, et al. WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology 2008;40:592-9
29. Köbel M, Piskorz A, Li S, et al. Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9 San Diego, CA. Philadelphia (PA): AACR. Cancer Res 2014;74(suppl). Abstract no. 1535.